Congenital Hyperinsulinism clinical trials at UCSF
1 research study open to new patients

• CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

  open to eligible people ages up to 12 months

  This is a Phase 2, multi-center, randomized, placebo-controlled, double-blind trial with open-label follow-up designed to assess the efficacy of Xeris Glucagon delivered as a continuous subcutaneous infusion to prevent hypoglycemia with lower intravenous glucose infusion rates in children < 1 year of age with congenital hyperinsulinism.

  San Francisco, California and other locations

Last updated: August 15, 2018